Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.303
Neutral
RSI(14)
42.219
Neutral
STOCH(KDJ)(9,3,3)
61.321
Buy
ATR(14)
1.085
Low Volatility
CCI(14)
-0.091
Neutral
Williams %R
56.653
Sell
TRIX(12,20)
-1.040
Sell
StochRSI(14)
100.000
Overbought
Search
Procept Biorobotics Corp
PRCTAdd to Watchlist
18.620USD
+0.620+3.44%
Close 07-31 16:00（ET）Quotes delayed by 15 min
1.06BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
+3.44%
5 Days
+11.56%
1 Month
-11.46%
6 Months
-36.10%
Year to Date
-40.81%
1 Year
-62.73%
Key Figures
18.010Open
18.670High
1.18MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
2.07%Turnover Ratio
18.000Prev. Close
17.710Low
16.50MTurnover
LossP/E Static
3.05P/B
0.00%Div Yield TTM
-20.36%ROA
66.85052wk High
0.93Volume Ratio
-91.41MNet Profit
56.90MShares
-1.8301EPS TTM
0.85Beta
-27.81%ROE
19.35052wk Low
5.33%Amplitude
64.89%Gross Margin
1.06BMarket Cap
-3.92Reward/Risk
3.87%Risk Rate
TradingKey Stock Score of Procept Biorobotics Corp
Currency: USD Updated: 2026-07-31Key Insights
Procept Biorobotics Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 23 out of 199 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 30.33.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Procept Biorobotics Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Procept Biorobotics Corp Highlights
StrengthsRisks
PROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company. The Company is focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The Company's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 126.19% year-on-year.
Overvalued
The company’s latest PE is -10.17, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 65.01M shares, decreasing 1.54% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 1.07M shares of this stock.
Analyst Rating
Based on
15
analysts
Buy
Current Rating
30.333
Target Price
+62.91%
Upside Space
Procept Biorobotics Corp News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
15
analysts
Buy
Current Rating
30.333
Target Price
+62.91%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
109
Total
7
Median
9
Average
Company name
Ratings
Analysts
Procept Biorobotics Corp
PRCT
15
Medtronic PLC
MDT
34
Stryker Corp
SYK
32
Dexcom Inc
DXCM
32
Zimmer Biomet Holdings Inc
ZBH
31
Abbott Laboratories
ABT
29
1
2
3
...
22
Indicators
Moving Average
Indicators
Value
Direction
MA5
18.054
Buy
MA10
17.995
Buy
MA20
19.036
Sell
MA50
22.675
Sell
MA100
23.938
Sell
MA200
27.540
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Procept Biorobotics Corp Info
PROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company. The Company is focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The Company's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.
Ticker SymbolPRCT
CompanyProcept Biorobotics Corp
CEOWood (Larry L)
Websitehttps://www.procept-biorobotics.com/
Shareholders
Related Instruments
-1.72%
-0.43%
+0.12%
-0.59%
-0.74%
-6.42%
+0.10%
-0.36%
+1.75%
-0.14%
-2.99%
+1.58%
-0.29%
+0.41%
-1.02%
+0.13%
+0.05%
-0.80%
-0.24%
-0.70%Popular Instruments
52773.700
+395.700 (+0.76%)
28528.700
+367.800 (+1.31%)
7536.200
+61.100 (+0.82%)
14610.000
-139.000 (-0.94%)
63753.000
+901.000 (+1.43%)
6398.700
+33.300 (+0.52%)
78.480
-7.454 (-8.67%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4069.160
+27.730 (+0.69%)
FAQs
What is the current price of Procept Biorobotics Corp (PRCT)?
The current price of Procept Biorobotics Corp (PRCT) is 18.62.
What is the symbol of Procept Biorobotics Corp?
The ticker symbol of Procept Biorobotics Corp is PRCT.
What is the 52-week high of Procept Biorobotics Corp?
The 52-week high of Procept Biorobotics Corp is 66.85.
What is the 52-week low of Procept Biorobotics Corp?
The 52-week low of Procept Biorobotics Corp is 19.35.
What is the market capitalization of Procept Biorobotics Corp?
The market capitalization of Procept Biorobotics Corp is 1.06B.
Is Procept Biorobotics Corp (PRCT) currently rated as Buy, Hold, or Sell?
According to analysts, Procept Biorobotics Corp (PRCT) has an overall rating of Buy, with a price target of 30.33.
What is the Earnings Per Share (EPS TTM) of Procept Biorobotics Corp (PRCT)?
The Earnings Per Share (EPS TTM) of Procept Biorobotics Corp (PRCT) is -1.72.